Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance.
PMID: 19358668
2009
The Journal of infectious diseases
Result: 3.1 +- 0.3 mumol/L, for Q151M and Q151M+3, respectively), indicating that A62V, F77L, and Y116F do not enhance AZT resistance in HIV-2.
Result: Although A62V, F77L, and Y116F increase the level of Q151M-mediated AZT resistance in HIV-1, the Q151M and Q151M+3 variants of HIV-2ROD exhibited comparable sensitivity to the drug (mean EC50 [+-SD], 5.2 +- 2.3 vs.
Result: Surprisingly, the dose-response profile of Q151M HIV-2ROD was comparable to that of the highly resistant Q151M/A62V/
PMID: 18487070
2008
The international journal of biochemistry & cell biology
Abstract: EFdA retains potency toward many HIV-1 resistant strains, including the multi-drug resistant clone HIV-1A62V/V75I/F77L/F116Y/Q151M.
Mutations at 65 and 70 within the context of a Q151M cluster in human immunodeficiency virus type 1 reverse transcriptase impact the susceptibility to the different nucleoside reverse transcriptase inhibitors in distinct ways.
PMID: 17567542
2007
Infection, genetics and evolution
Abstract: The original isolate carried the MNR mutations S68G, V75I, F77L, F116Y and Q151M, the lamivudine mutation M184V, the NNRTI mutation K103N and the yet unreported K70S.
HIV-1 subtype B protease and reverse transcriptase amino acid covariation.
PMID: 16048947
2005
Antimicrobial agents and chemotherapy
Abstract: In contrast, the susceptibility of the virus carrying the K65R mutation or the multidrug-resistant mutation with the Q151M complex (A62V, V75I, F77L, F116Y, and Q151M) was not altered.
Substitutions in the Reverse Transcriptase and Protease Genes of HIV-1 Subtype B in Untreated Individuals and Patients Treated With Antiretroviral Drugs.
PMID: 19825125
2005
Journal of the International AIDS Society
Table: F77L
Drug-resistance mutations in antiretroviral-naive patients with established HIV-1 infection in Mexico.
Abstract: At the enzyme level, the addition of the A62V mutation to V75I/F77L/F116Y/Q151M moderately (3.4-fold) reversed the resistance to DXG-TP.
Abstract: In this study, we evaluated the antiviral activity of (-)-beta-D-1',3'-dioxolan guanine (DXG) towards mutant HIV-1 containing V75I/F77L/F116Y/Q151M (V75Icomplex) and A62V/V75I/F77L/F116Y/Q151M (A62Vcomplex) in MT-2 cells.
Abstract: The multi-drug resistance HIV-1 genotype A62V/V75I
Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
Abstract: Of these viruses, 9 (25.7%) had only secondary TAMs (D67N, K219Q, M41L, or F77L), and all were found to be sensitive to zidovudine (AZT) and other drugs.
The molecular mechanism of multidrug resistance by the Q151M human immunodeficiency virus type 1 reverse transcriptase and its suppression using alpha-boranophosphate nucleotide analogues.
PMID: 12194983
2002
The Journal of biological chemistry
Abstract: The appearance of up to five substitutions (A62V, V75I, F77L, F116Y, and Q151M) in the viral reverse transcriptase promotes resistance to these drugs, and reduces efficiency of the antiretroviral chemotherapy.
Abstract: Using A62V/V75I/F77L/F116Y/Q151M RT, k(pol) increases up to 70- and 13-fold using alpha-boranophosphate-ddATP and alpha-boranophosphate AZTTP, respectively.
Abstract: Using pre-steady state kinetics, we show that Q151M and A62V/